Balaji Amines Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Stable quarter, execution-focused tone: EBITDA margin improved to 19% from 17% QoQ despite mixed demand in pharma and agrichem, with management emphasizing operational execution and near-term commissioning milestones.
• The capex cycle is the story: Multiple projects across DME, DMC, NMP, acetonitrile and Balaji Specialty Chemicals are approaching commissioning, with management guiding minimum 15% growth in values and volumes next financial year as these assets come online.
• Battery-grade products are ready, customers are not: DMC and NMP are technically commissioned with trial batches delivered, but battery manufacturers have not yet placed bulk orders, leaving utilization at 20% and the ramp-up timeline dependent on customer readiness.
• Brownfield modifications are suppressing current utilization: Balaji Specialty Chemicals is running at very low utilization because the same plant is being modified in cycles, a constraint that persists through Q4 FY26 and masks the asset's true earnings power.
• What to watch next quarter: DME cylinder approval and plant commissioning, any bulk orders from battery manufacturers, the acetonitrile antidumping investigation outcome, and whether pharma/agro demand normalizes as guided.

Project Pipeline & Commissioning Timeline

• DME plant: Valve approval for cylinders received 15 days ago; cylinder permission expected in 2–3 weeks; plant will be commissioned upon receipt, before end of Q3 FY26.
• DMC and NMP battery-grade: Both products are ready with trial batches given to 1–2 battery manufacturers; customers indicate bulk quantities required from December or April onwards, but management cannot predict their exact timeline.
• Acetonitrile technology upgrade: Existing plant running at 5–10% capacity on-and-off while equipment is changed to latest technology for very high-purity material at low manufacturing cost; completion expected Q1 FY27.
• N-Methyl Morpholine: Commissioning expected by end of current quarter (Q3 FY26).
• Dimethyl carbonate: Ready for commissioning; expected first week of next quarter (Q4 FY26).
• Unit 1 brownfield expansion (EDA-based products): Expected commissioning by September 2026.
• Unit 2 greenfield at Chincholi: Equipment installation underway; expected commissioning by December 2026.
• Balaji Specialty brownfield modifications: Expected to finish by start of next financial year (Q1 FY27), after which actual capacity utilization of Unit 1 will be visible.
• Balaji Specialty Unit 2 expansions: At least 1–2 plants expected to start commissioning in Q2 FY27.
• All ongoing projects: Funded through internal accruals.

D. Ram Reddy: "As per the latest technology, we are going to produce the very high-purity material at a low-cost manufacturing cost, which will take at least first quarter of the next financial year."

Demand Environment & End Markets

• Domestic stability: 80–90% of the market is stable; amines and intermediates demand is steady domestically, with exports showing some volatility due to direct and indirect tariffs on end users.
• Pharma and agro recovery: Demand was very slow in the past 1–2 quarters but is slowly picking up; management expects improvement to normal levels in coming quarters.
• Export trajectory: Exports faced higher freight costs in the past, now stable; pharma and agro industries were lower so expected export levels were not achieved; improvement expected in coming quarters.
• Export contracts: Some contracts with US and Europe have been continued, and signals received for continuation in the coming financial year.
• Chinese import competition: Only 1–2 products compete with Chinese imports; dimethylformamide is the main product facing competition, which has been ongoing for several years.
• Pharma customer backward integration: One pharma customer backward integrated into methylamines for captive consumption with excess to sell; management has not seen major impact as of now, noting the plant is locationally in Gujarat while major customers are in Maharashtra and South.
• Acetonitrile demand: Domestic consumption expected to grow at minimum 7–8%; once 60 tons per day capacity commences, both exports and domestic sales will increase.
• Antidumping support: Ministry has imposed antidumping on acetonitrile.

Battery-Grade Products: The Waiting Game

• DMC utilization at 20%: Plant is commissioned but operating at low capacity because battery manufacturers have not yet taken off into full swing.
• Customer readiness unknown: Management states it is "very difficult to tell" why domestic EV battery manufacturers have not ramped up, deferring to the customers' own timelines.
• Bulk order signals: Battery manufacturers indicate bulk quantities required from December or April onwards; management is "just waiting for their kick start."
• NMP trial batches delivered: Battery-grade NMP is ready; trial batches given to 1–2 battery manufacturers.
• Electronic-grade DMC and pharma-grade PG: Financial contribution expected to be more visible in coming quarters, aligned with import substitution theme; pharma-grade PG license has been applied for and manufacturing will start once obtained.

D. Ram Reddy: "They are saying that — somebody says that by December and somebody says that from April onwards, they will be requiring bulk quantities. We were just waiting for their kick start."

Balaji Specialty Chemicals: Utilization Masked by Modifications

• Current utilization very low: Plant runs 15–20 days, then stops for brownfield modifications; this cycle will continue through Q3 and Q4 FY26.
• Revenue flat in H2: Second half revenue expected to be same as first half (₹70 crores); if antidumping comes, there may be improvement in bottom line, but real benefits only after modifications are complete in the coming financial year.
• Mega project status granted: ₹750 crores expansion plan granted mega project status under Maharashtra government's Package Scheme of Incentives 2019.
• Acetonitrile operations: Plant runs 10 days, then stops for modifications; 20 days of modification work, then another 10 days of manufacturing; prices stable at ₹140–₹150; inventory maintained by producing in 10-day batches.

Margins & Cost Structure

• EBITDA margin improved: 19% in Q2 FY26, up from 17% in Q1 FY26, reflecting sustained healthy margins and efficient operations amid mixed demand.
• Management's margin range: Reasonably maintain 20–22%; lowest 17.5–18%; maximum 24% in the current competitive environment.
• Green energy cost advantage: Almost 80% of manufacturing now powered by solar, via rooftop panels and a separate solar park.
• Working capital normal: Receivable cycle at 60–90 days; management characterizes it as "almost normal only."

D. Ram Reddy: "With a reasonable EBITDA, we should be in a position to maintain 20% to 22%. And with the lowest, it should be 17.5% to 18% and maximum is 24%, what we can see in the current competitive environment."

Regulatory & Trade Developments

• EDA antidumping investigation: Oral hearing held; investigating officer retired, case allotted to new officer; another hearing expected by month-end, results possibly by end of next month.
• Acetonitrile antidumping: Ministry has imposed antidumping on acetonitrile.
• DME LPG blending: Proposal already submitted to the government and is "moving table to table in the Government of India."
• Pharma-grade PG license: Applied for; manufacturing will start once license is obtained.

D. Ram Reddy: "The LPG blending, we've already given to the government. It is in the moving table to table in the Government of India."

Guidance & Commitments

Key Metrics